Preventing antimalarial drug resistance with triple artemisinin-based combination therapies
© 2023. The Author(s)..
Increasing levels of artemisinin and partner drug resistance threaten malaria control and elimination globally. Triple artemisinin-based combination therapies (TACTs) which combine artemisinin derivatives with two partner drugs are efficacious and well tolerated in clinical trials, including in areas of multidrug-resistant malaria. Whether early TACT adoption could delay the emergence and spread of antimalarial drug resistance is a question of vital importance. Using two independent individual-based models of Plasmodium falciparum epidemiology and evolution, we evaluated whether introduction of either artesunate-mefloquine-piperaquine or artemether-lumefantrine-amodiaquine resulted in lower long-term artemisinin-resistance levels and treatment failure rates compared with continued ACT use. We show that introduction of TACTs could significantly delay the emergence and spread of artemisinin resistance and treatment failure, extending the useful therapeutic life of current antimalarial drugs, and improving the chances of malaria elimination. We conclude that immediate introduction of TACTs should be considered by policy makers in areas of emerging artemisinin resistance.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Nature communications - 14(2023), 1 vom: 29. Juli, Seite 4568 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nguyen, Tran Dang [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 31.07.2023 Date Revised 02.08.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41467-023-39914-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360166156 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360166156 | ||
| 003 | DE-627 | ||
| 005 | 20231226082431.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41467-023-39914-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1200.xml |
| 035 | |a (DE-627)NLM360166156 | ||
| 035 | |a (NLM)37516752 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nguyen, Tran Dang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Preventing antimalarial drug resistance with triple artemisinin-based combination therapies |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.07.2023 | ||
| 500 | |a Date Revised 02.08.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a Increasing levels of artemisinin and partner drug resistance threaten malaria control and elimination globally. Triple artemisinin-based combination therapies (TACTs) which combine artemisinin derivatives with two partner drugs are efficacious and well tolerated in clinical trials, including in areas of multidrug-resistant malaria. Whether early TACT adoption could delay the emergence and spread of antimalarial drug resistance is a question of vital importance. Using two independent individual-based models of Plasmodium falciparum epidemiology and evolution, we evaluated whether introduction of either artesunate-mefloquine-piperaquine or artemether-lumefantrine-amodiaquine resulted in lower long-term artemisinin-resistance levels and treatment failure rates compared with continued ACT use. We show that introduction of TACTs could significantly delay the emergence and spread of artemisinin resistance and treatment failure, extending the useful therapeutic life of current antimalarial drugs, and improving the chances of malaria elimination. We conclude that immediate introduction of TACTs should be considered by policy makers in areas of emerging artemisinin resistance | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antimalarials |2 NLM | |
| 650 | 7 | |a Artemether |2 NLM | |
| 650 | 7 | |a C7D6T3H22J |2 NLM | |
| 650 | 7 | |a Artemether, Lumefantrine Drug Combination |2 NLM | |
| 650 | 7 | |a artemisinin |2 NLM | |
| 650 | 7 | |a 9RMU91N5K2 |2 NLM | |
| 650 | 7 | |a Artemisinins |2 NLM | |
| 650 | 7 | |a Folic Acid Antagonists |2 NLM | |
| 700 | 1 | |a Gao, Bo |e verfasserin |4 aut | |
| 700 | 1 | |a Amaratunga, Chanaki |e verfasserin |4 aut | |
| 700 | 1 | |a Dhorda, Mehul |e verfasserin |4 aut | |
| 700 | 1 | |a Tran, Thu Nguyen-Anh |e verfasserin |4 aut | |
| 700 | 1 | |a White, Nicholas J |e verfasserin |4 aut | |
| 700 | 1 | |a Dondorp, Arjen M |e verfasserin |4 aut | |
| 700 | 1 | |a Boni, Maciej F |e verfasserin |4 aut | |
| 700 | 1 | |a Aguas, Ricardo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 14(2023), 1 vom: 29. Juli, Seite 4568 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g number:1 |g day:29 |g month:07 |g pages:4568 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-023-39914-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2023 |e 1 |b 29 |c 07 |h 4568 | ||